A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Recruiting

Phase 2

Phase 3

Frexalimab vs. TacrolimusA Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Sponsor:

Sanofi

Code:

NCT07412470

Conditions

Kidney Transplant Rejection

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Frexalimab

Tacrolimus

rabbit anti-thymocyte globulin

mycophenolate mofetil

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-27. This information was provided to ClinicalTrials.gov by Sanofi on 2026-06-23.